Program
Poliovirus Vaccine, Oral
Also written as “Polio Sabin™”, “Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)” and “sIPV+bOPV”.
Its studies are mostly in Streptococcal Infections · Poliomyelitis · Tuberculosis · Hepatitis B · Rotavirus Infections, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 40 open or running | phase 3since Oct 19, 2007 | Oct 19, 2007 | none ahead |
| Beijing Minhai Biotechnology | 10 open or running | phase 3since Dec 12, 2024 | Dec 12, 2024 | none ahead |
| Merck | 10 open or running | phase 3since Aug 12, 2005 | Aug 12, 2005 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 12, 2005First study: phase 3 study in Rotavirus InfectionsNew to MerckMerck · NCT00130832 · 735 enrolled
- Oct 19, 2007GlaxoSmithKline’s first study: phase 3 study in Streptococcal InfectionsNew to GlaxoSmithKlineGlaxoSmithKline · NCT00547248 · 756 enrolled · Philippines, Poland
- Mar 18, 2010Phase 2 study in TuberculosisGlaxoSmithKline · NCT01098474 · 301 enrolled · Gambia
- Dec 2, 2010Phase 2 study in Streptococcal InfectionsGlaxoSmithKline · NCT01262872 · 1,320 enrolled · Gambia
- Oct 20, 2011Phase 3 study in Hepatitis BGlaxoSmithKline · NCT01457560 · 80 enrolled
- Dec 12, 2024Beijing Minhai Biotechnology’s first study: phase 3 study in PoliomyelitisNew to Beijing Minhai BiotechnologyBeijing Minhai Biotechnology · NCT06752174 · 300 enrolled · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06752174Poliomyelitis · China | 3 | Completed | Beijing Minhai Biotechnology | Apr 12, 2024 | 300 |
| NCT01457560Hepatitis B | 3 | Completed | GlaxoSmithKline | Apr 2001 | 80 |
| NCT01262872Streptococcal Infections · Gambia | 2 | Completed | GlaxoSmithKline | Mar 18, 2013 | 1,320 |
| NCT01098474Tuberculosis · Gambia | 2 | Completed | GlaxoSmithKline | Apr 30, 2011 | 301 |
| NCT00547248Streptococcal Infections · Philippines, Poland | 3 | Completed | GlaxoSmithKline | May 10, 2008 | 756 |
| NCT00130832Rotavirus Infections | 3 | Completed | Merck | Jul 2006 | 735 |
How it is read
Names in the registry
- “Polio Sabin™”, 2 entries
- “Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)”, 1 entry
- “sIPV+bOPV”, 1 entry
- “Polio Sabin”, 1 entry
- “bOPV”, 1 entry
Conditions, from the studies’ own filings
- Streptococcal Infections, 2 studies
- Poliomyelitis, 1 study
- Tuberculosis, 1 study
- Hepatitis B, 1 study
- Rotavirus Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.